{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-002574","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2025-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.518739+00:00","generated_at":"2026-05-23T17:21:08.081162+00:00","sec_items":["3.03"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"BioNexus Gene Lab Corp. effects 1-for-10 reverse stock split effective April 7, 2025","bullets":["1-for-10 reverse split effective 12:01 a.m. ET April 7, 2025; shares reduced from 17,967,663 to 1,796,597.","No fractional shares issued; cash payment based on 10-day VWAP prior to effective date (corrects prior cash payment price).","Reverse split aims to regain compliance with Nasdaq Minimum Bid Price Rule by May 1, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-002574","json":"https://secwatch.observer/filing/0001477932-25-002574.json","markdown":"https://secwatch.observer/filing/0001477932-25-002574.md","text":"https://secwatch.observer/filing/0001477932-25-002574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225002574/0001477932-25-002574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225002574/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T17:21:08.081162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}